IN2014MN02126A - - Google Patents
Info
- Publication number
- IN2014MN02126A IN2014MN02126A IN2126MUN2014A IN2014MN02126A IN 2014MN02126 A IN2014MN02126 A IN 2014MN02126A IN 2126MUN2014 A IN2126MUN2014 A IN 2126MUN2014A IN 2014MN02126 A IN2014MN02126 A IN 2014MN02126A
- Authority
- IN
- India
- Prior art keywords
- compounds
- calcium
- crac
- channel
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 2
- 150000001669 calcium Chemical class 0.000 abstract 2
- 229910052791 calcium Inorganic materials 0.000 abstract 2
- 239000011575 calcium Substances 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2126MUN2014 IN2014MN02126A (OSRAM) | 2012-05-02 | 2013-05-01 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN6KO2012 | 2012-05-02 | ||
| PCT/IB2013/053440 WO2013164769A1 (en) | 2012-05-02 | 2013-05-01 | Substituted pyridine compounds as crac modulators |
| IN2126MUN2014 IN2014MN02126A (OSRAM) | 2012-05-02 | 2013-05-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02126A true IN2014MN02126A (OSRAM) | 2015-09-11 |
Family
ID=48428565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2126MUN2014 IN2014MN02126A (OSRAM) | 2012-05-02 | 2013-05-01 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9399638B2 (OSRAM) |
| EP (1) | EP2844655A1 (OSRAM) |
| AU (1) | AU2013255437A1 (OSRAM) |
| CA (1) | CA2871270A1 (OSRAM) |
| IN (1) | IN2014MN02126A (OSRAM) |
| WO (1) | WO2013164769A1 (OSRAM) |
| ZA (1) | ZA201407685B (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| EP3010586A1 (en) | 2013-06-21 | 2016-04-27 | Lupin Limited | Substituted heterocyclic compounds as crac modulators |
| AU2014300629A1 (en) | 2013-06-24 | 2015-12-24 | Lupin Limited | Chromane and chromene derivatives and their use as CRAC modulators |
| WO2015090579A1 (en) * | 2013-12-18 | 2015-06-25 | Grünenthal GmbH | Pyrazolyl-based carboxamides iv |
| CN105367547B (zh) * | 2014-08-19 | 2019-04-23 | 北京桦冠生物技术有限公司 | 一种噁唑啉酮抗生素的新合成工艺 |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| JP2018500388A (ja) | 2014-11-18 | 2018-01-11 | ラットガーズ、ザ ステート ユニバーシティ オブ ニュージャージー | 代謝疾患及び癌の治療のための、新規ミトコンドリアアンカップラー |
| EA036265B1 (ru) * | 2015-02-27 | 2020-10-20 | Кальцимедика, Инк. | Лечение панкреатита |
| WO2016187182A1 (en) | 2015-05-18 | 2016-11-24 | Beth Israel Deaconess Medical Center, Inc. | Substance p, mast cell degranulation inhibitors, and peripheral neuropathy |
| DK3303330T3 (da) | 2015-06-03 | 2019-08-05 | Bristol Myers Squibb Co | 4-hydroxy-3-(heteroaryl)pyridin-2-on-apj-agonister til anvendelse i behandlingen af kardiovaskulære forstyrrelser |
| DK3331525T3 (da) | 2015-08-07 | 2020-12-14 | Calcimedica Inc | Anvendelse af CRAC-kanal-inhibitorer til behandling af slagtilfælde og traumatisk hjerneskade |
| EP3458454B1 (en) | 2016-05-18 | 2021-11-24 | Rutgers, The State University of New Jersey | 2-hydroxy-n-(benzo[d]thiazol-2-yl)benzamide derivatives as mitochondrial uncouplers for the treatment of metabolic diseases and cancer |
| WO2018051306A1 (en) | 2016-09-19 | 2018-03-22 | Novartis Ag | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
| PL3618875T3 (pl) | 2017-05-02 | 2023-10-23 | Novartis Ag | Terapia skojarzona obejmująca inhibitor raf i trametynib |
| JP7446236B2 (ja) * | 2017-12-22 | 2024-03-08 | ラヴェンナ ファーマシューティカルズ，インコーポレイテッド | ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアリール－ビピリジンアミン誘導体 |
| CN112074505B (zh) | 2018-03-08 | 2024-04-05 | 因赛特公司 | 作为PI3K-γ抑制剂的氨基吡嗪二醇化合物 |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| US20220040162A1 (en) | 2018-09-14 | 2022-02-10 | Rhizen Pharmaceuticals Ag | Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof |
| EP3969449B1 (en) | 2019-05-13 | 2025-02-12 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer |
| CN110407740A (zh) * | 2019-09-04 | 2019-11-05 | 上海毕得医药科技有限公司 | 一种3-溴-2-乙基吡啶的合成方法 |
| WO2023210599A1 (ja) | 2022-04-25 | 2023-11-02 | 日本新薬株式会社 | Ｄｄｒ１キナーゼ阻害剤としての化合物および医薬 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2533594C (en) | 2003-07-23 | 2013-04-02 | Synta Pharmaceuticals, Corp. | Compounds for inflammation and immune-related uses |
| BRPI0515546A (pt) | 2004-09-21 | 2008-07-29 | Syntha Pharmaceuticals Corp | compostos para inflamação e usos imune-relacionados |
| KR20140018997A (ko) | 2005-01-07 | 2014-02-13 | 신타 파마슈티칼스 코프. | 염증 및 면역 관련 용도를 위한 화합물 |
| WO2006081389A1 (en) | 2005-01-25 | 2006-08-03 | Synta Pharmaceuticals Corp. | Thiophene compounds for inflammation and immune-related uses |
| EP1848435B1 (en) | 2005-01-25 | 2016-01-20 | Synta Pharmaceuticals Corp. | Compounds against inflammations and immune-related uses |
| EP1983971A4 (en) | 2006-01-25 | 2010-11-24 | Synta Pharmaceuticals Corp | SUBSTITUTED AROMATIC COMPOUNDS FOR USE AGAINST INFLAMMATION AND IMMUNE DISORDERS |
| CA2639927A1 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Substituted biaryl compounds for inflammation and immune-related uses |
| US20070275960A1 (en) | 2006-01-25 | 2007-11-29 | Synta Pharmaceuticals Corp. | Phenyl and pyridyl compounds for inflammation and immune-related uses |
| ES2403368T3 (es) | 2006-01-31 | 2013-05-17 | Synta Pharmaceuticals Corporation | Compuestos de piridilfenilo para la inflamación y usos inmunorrelacionados |
| EP2069359B1 (en) | 2006-08-21 | 2014-11-12 | Genentech, Inc. | Aza-benzothiophenyl compounds and methods of use |
| WO2009017819A1 (en) | 2007-08-01 | 2009-02-05 | Synta Pharmaceuticals Corp. | Pyridine compounds for inflammation and immune-related uses |
| CN102648198B (zh) | 2007-08-17 | 2015-04-01 | 埃科特莱茵药品有限公司 | 作为s1p1/edg1受体调节剂的吡啶衍生物 |
| JP5411141B2 (ja) | 2007-09-10 | 2014-02-12 | カルシメディカ，インク． | 細胞内カルシウムを調節する化合物 |
| US8389567B2 (en) | 2007-12-12 | 2013-03-05 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| NZ589062A (en) | 2008-05-23 | 2012-06-29 | Glaxo Group Ltd | Tricyclic nitrogen containing compounds and their use as antibacterials |
| DE102008031299B4 (de) | 2008-07-02 | 2014-10-30 | Acandis Gmbh & Co. Kg | Filter für ein Blutgefäß |
| KR101724161B1 (ko) | 2008-08-27 | 2017-04-06 | 칼시메디카, 인크 | 세포내 칼슘을 조절하는 화합물 |
| US8524763B2 (en) | 2008-09-22 | 2013-09-03 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
| WO2010039238A1 (en) | 2008-10-01 | 2010-04-08 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| TW201111380A (en) | 2009-08-26 | 2011-04-01 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
| US8618307B2 (en) | 2009-09-16 | 2013-12-31 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| ES2578290T3 (es) | 2010-10-30 | 2016-07-22 | Lupin Limited | Derivados de oxazolina e isoxazolina como moduladores de CRAC |
| CN103702665B (zh) | 2011-05-03 | 2016-08-17 | 幸讬制药公司 | 用于炎症和免疫相关用途的化合物 |
| US20140256771A1 (en) | 2011-10-19 | 2014-09-11 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2013059677A1 (en) | 2011-10-19 | 2013-04-25 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
-
2013
- 2013-05-01 EP EP13722111.5A patent/EP2844655A1/en not_active Withdrawn
- 2013-05-01 CA CA2871270A patent/CA2871270A1/en not_active Abandoned
- 2013-05-01 AU AU2013255437A patent/AU2013255437A1/en not_active Abandoned
- 2013-05-01 US US14/398,154 patent/US9399638B2/en not_active Expired - Fee Related
- 2013-05-01 IN IN2126MUN2014 patent/IN2014MN02126A/en unknown
- 2013-05-01 WO PCT/IB2013/053440 patent/WO2013164769A1/en not_active Ceased
-
2014
- 2014-10-22 ZA ZA2014/07685A patent/ZA201407685B/en unknown
-
2016
- 2016-06-20 US US15/186,882 patent/US20160304506A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201407685B (en) | 2015-11-25 |
| AU2013255437A1 (en) | 2014-11-13 |
| CA2871270A1 (en) | 2013-11-07 |
| US20150111900A1 (en) | 2015-04-23 |
| WO2013164769A1 (en) | 2013-11-07 |
| US9399638B2 (en) | 2016-07-26 |
| EP2844655A1 (en) | 2015-03-11 |
| US20160304506A1 (en) | 2016-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02126A (OSRAM) | ||
| IN2014MN02127A (OSRAM) | ||
| CU24036B1 (es) | Derivados de benzofuranilo | |
| TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
| MX2013012896A (es) | Compuestos novedosos como moduladores de proteina cinasas. | |
| GEP20166438B (en) | Imidazopyrrolidinone compounds | |
| PH12015500551A1 (en) | Tricyclic quinoline and quinoline derivatives | |
| CR20110103A (es) | Heteroarilos sustituidos | |
| IN2014CN04907A (OSRAM) | ||
| MD20140109A2 (ro) | Compuşi ai indolului şi indazolului care activează AMPK | |
| PH12014502757B1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| MX367420B (es) | Metodos y composiciones para inhibicion de proteinas que contienen bromodominio. | |
| WO2012170931A3 (en) | Compounds that modulate intracellular calcium | |
| IN2012DN00943A (OSRAM) | ||
| MX2015012867A (es) | Compuestos aromaticos multisustituidos como inhibidores de serina proteasa. | |
| MX337711B (es) | Compuestos que modulan el calcio intracelular. | |
| TN2013000346A1 (en) | Asymmetric ureas and medical uses thereof | |
| MY162689A (en) | Oxazoline and isoxazoline derivatives as crac modulators | |
| PH12014501979B1 (en) | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor | |
| AU2011322715A8 (en) | Treatment of MeCP2-associated disorders | |
| PH12014501891B1 (en) | Substituted chroman compounds as calcium sensing receptor modulators | |
| UY36081A (es) | Compuestos inhibidores de metaloenzima como fungicidas. | |
| WO2012170951A3 (en) | Compounds that modulate intracellular calcium | |
| TW201613878A (en) | Pyrazine GPR40 agonists for the treatment of type II diabetes | |
| HK1220699A1 (zh) | 治疗神经退行性蛋白质病的化合物 |